Pronec
Alderley Park
About Pronec
Pronec Ltd seeks to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides. The Company has identified a lead candidate molecule that causes necrosis of a wide range of tumour cell lines in culture, but does not affect normal cell lines. Cancer cell necrosis refers to death of cancer cells within a tumour. This new class of compounds is protected by GB and international patent applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $73.7K
- Funding stage: Seed
- Last round: Seed (Jan 2016)
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/pronec-3103810 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.